Ara
Toplam kayıt 2, listelenen: 1-2
Gilteritinib (XOSPATA (R)) in Turkey: Early access program results
(Mattioli 1885, 2023)
Background And Objectives: Gilteritinib (XOSPATA (R), Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor, involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ...
Long-term prognosis of patients with heart failure: Follow-up results of journey HF-TR study population
(Turkish Society of Cardiology, 2023)
Background: Despite advances in therapeutic management of patients with heart failure, there is still an increasing morbidity and mortality all over the world. In this study, we aimed to present the 3-year follow-up outcomes ...